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http://www.springerplus.com/content/3/1/492CASE STUDY Open AccessFusarium napiforme systemic infection: case
report with molecular characterization and
antifungal susceptibility tests
Marcela de Souza1,4*, Tetsuhiro Matsuzawa2, Luzia Lyra3, Ariane Fidelis Busso-Lopes1, Tohru Gonoi2,
Angélica Zaninele Schreiber3, Katsuhiko Kamei2, Maria Luiza Moretti1 and Plínio Trabasso1Abstract
Introduction: During the last decades, Fusarium spp. has been reported as a significant cause of disease in
humans, especially in immunocompromised patients, who have high risk of invasive life-threatening disease.
Fusarium species usually reported as cause of human disease are F. solani, F. oxysporum and F. verticillioides.
Case description: We describe the second case in the literature of disseminated fusariosis caused by Fusarium
napiforme, that occurred in a 60-year-old woman with multiple myeloma after subsequent cycles of chemotherapy.
Discussion and Evaluation: We identified the F. napiforme not only by standard morphologic criteria by
macroscopic and microscopic characteristics, but also confirmed by molecular biology methods, including
sequencing. The antifungal susceptibility of the F. napiforme isolates were tested to seven antifungal drugs; the
azoles were the most active drug against all the isolates tested.
Conclusions: Fusarium spp. are of relevance in medical mycology, and their profiles of low susceptibility to
antifungal drugs highlight the importance for faster and more accurate diagnostic tests, what can contribute to an
earlier and precise diagnosis and treatment.
Keywords: Fusariosis; Opportunistic Infections; Immunocompromised hostBackground
Fusarium are widely distributed fungi in soil, plants, plant
debris and other organic substrates, and in water systems.
During the last decades, Fusarium spp. has been reported
as a significant cause of disease in humans, especially im-
munocompromised patients (Jureen et al. 2008; Bourgeois
et al. 2010; De Pinho et al. 2012; Calcaterra et al. 2013).
In immunocompetent persons, Fusarium usually causes
localized infections (Bourgeois et al. 2010; De Pinho et al.
2012; Calcaterra et al. 2013; Homa et al. 2013). Con-
versely, immunocompromised hosts, mainly those with
acute onco-hematological diseases or after allogeneic
hematopoietic stem cell transplant, have high risk of inva-
sive life-threatening diseases. In such patients, invasive* Correspondence: marceladesouza88@gmail.com
1Department of Internal Medicine, School of Medicine, University of
Campinas, Campinas, São Paulo, Brazil
4LIM 46 – Laboratory of Parasitology – HC/FMUSP, São Paulo, Brazil
Full list of author information is available at the end of the article
© 2014 de Souza et al.; licensee Springer. This
Attribution License (http://creativecommons.or
in any medium, provided the original work is pfusariosis (IF) is relatively resistant to standard antifungal
therapy limiting their treatment options (Scheel et al.
2013; Pereira et al. 2013).
Fusarium species reported as cause of human disease
and F. solani, F oxysporum and F. verticillioides are the
most frequently species causing IF (Gupta et al. 2000;
Tezcan et al. 2009).
The first case of disseminated fusariosis was described in
1973 (Cho et al. 1973). Since then, there was a significant
increase in the occurrence of disseminated disease, prob-
ably reflecting the increase in number of immunocom-
promised hosts (Bourgeois et al. 2010). There are reports
of IF worldwide (Martino et al. 1994; Nucci and Anaissie
2007; Tortorano et al. 2008; Slavin et al. 2012; Nucci et al.
2013). The first case of disseminated fusariosis due to
F. napiforme was described in 1993 (Melcher et al. 1993)
but, there were no subsequent reports of disseminated dis-
ease. Thus, to our knowledge, we describe the second
case of the literature of disseminated fusariosis caused byis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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by molecular biology methods, including sequencing.
Case description and molecular identification of
the clinical isolates
Case description
A 60-year-old woman was diagnosed with stage IIIB
multiple myeloma (MM) in 2005. She was treated with
chemotherapy, 6 cycles of VAD (vincristine + doxorubi-
cin + dexamethasone) in 2006, then cyclophosphamide
in 2007. This treatment was followed by an autologous
bone marrow transplant in 2008. The disease relapsed in
October 2010. She underwent decompressing lumbar
spine surgery in 2010 and received various courses of
treatment with zoledronic acid throughout her follow-
up. The patient had also radiotherapy in 2009 (spine)
and 2011 (spleen), followed by salvage chemotherapy
throughout 2011 (cyclophosphamide + thalidomide +
dexamethasone-CTD, then velcade + thalidomide + dexa-
methasone-VTD, and finally cyclophosphamide + pred-
nisone). At this point she was considered to present a
very good partial response (VGPR). In October 2012,
during a routine medical consultation, she complained
of palpitation and dyspnea starting 10 days before. The
patient presented with hypercalcemia and had to be ad-
mitted for the treatment of this condition. During the
admission, a second BMT was proposed to treat the re-
fractory MM; therefore, myelosuppressive chemotherapy
was initiated. After one week the neutrophil count fell
to zero and painful vasculitis lesions arose in lower
abdominal region and in the left thigh. Blood cultures
were withdrawn and skin biopsy was performed. Anti-
microbial therapy was started with cefepime and ampho-
tericin B deoxycholate. Blood culture resulted positive
for Pseudomonas aeruginosa and cefepime was switched
to imipenem. After one week of this regimen, patient
was still neutropenic, febrile and worsening clinical con-
ditions. A new set of blood cultures was positive for Fu-
sarium sp. The skin biopsy showed a large number of
hyphae using direct microscopic exam, morphologically
compatible with fusariosis. The patient died in Novem-
ber due to refractory septic shock.
Fusarium samples
Four clinical isolates of Fusarium sp. from clinical speci-
mens were identified as: LIF 2008, 2009 and 2010 recov-
ered from blood cultures (BacT/ALERT® 3D, bioMérieux
AS, France), LIF 1994 from skin biopsy and F111 from
the air of the patient’s hospital room.
Microorganism identification
The five clinical isolates were cultured in Sabouraud
Dextrose agar (Difco, Sparks, Maryland, USA) andidentified by morphologic criteria after subculture by
macroscopic and microscopic characteristics (Verweij et al.
2007).
Molecular methods
DNA extraction of Fusarium spp. from blood culture
bottles, from skin biopsy and from air were performed
using Dr. GenTLE® kit (Takara, Otusu, Shiga, Japan).
After DNA measurement in NanoDrop 2000 (Thermo
Scientific, Wilmington, USA) and equalization to a con-
centration of 2 ng/μL, DNA samples were analyzed
using: DNA microarray and DNA sequencing.
The DNA microarray was performed as described by
(Ferrari et al. 2013), the oligonucleotide probes, consist-
ing of 14 to 20 species-specific nucleotide sequences
with biotin-labeled poly T anchors at the end of each
nucleotide (Invitrogen, Showajima, Japan), were designed
based on ITS1 and ITS2 sequences of the Type strains
[GenBank database, American Type Culture Collection
(ATCC), Centraalbureau voor Schimmelcultures (CBS)
and MMRC-Chiba (IFM)]. Multiple-sequence alignments
were performed using the BioEdit software (version 7.1.3.
[http://www.mbio.ncsu.edu/BioEdit/bioedit.html]). Conserved
regions were also used as targets for genus-specific probes
or as controls. The probe sequences were spotted onto
a plastic slide (NGK Insulators LTD, Aichi, Japan) using
a KCS mini microarray printer (Kubota Comps. Corpor-
ation, Amagasaki, Japan). For fungal identification, PCR
using universal fungal primers ITS1 (5′-TCCGTAGGTG
AACCTGCGG-3′) and ITS4 (5′-TCCTCCGCTTATTGA
TATGC-3′) (Sigma-Aldrich, Saint Louis, USA) were used
to amplify the ITS regions (ITS1 and ITS2) and the 5.8S
rRNA gene followed by hybridization, conjugation, color-
ation and direct visualization of specifically positioned
spots on the slide that were consisted of 23 fungal species.
The sequencing was performed as described before
(Moreira-Oliveira et al. 2005), with modifications. First,
we performed a polymerase chain reaction (PCR) to
amplify a region of the gene EF1α using the pairs of
primers forward HS392 (5′-TCAAAATGGGTAAGGA
(A/G)GACAAGAC-3′) and HS393 (5′-GCCTGGGA(G/
A)GTACCAGT(G/C)ATCATGTT-3′). The PCR prod-
ucts were directly sequenced with a BigDye© terminator
reagent kit (Applied Biosystems, Foster City, CA) in an
automated DNA sequencer (3110 AB System, Applied
Biosystems, Foster City, USA). Besides HS392 and HS393
primers, two internal initiators were used for sequencing
reaction and amplification of EF1α gene: EF11 (5′-GTGG
GGCATTTACCCCGCC-3′) and EF21 (5′-GAGTGGCG
GGGTAAATGCC-3′). The sequences were assembled
using ATSQ version 6.0.1 (Genetix) and compared with
database information available at NCBI bank (National
Center for Biotechnology Information, http://blast.ncbi.
nlm.nih.gov/Blast.cgi). Sequences alignment was carried
Figure 1 Representative hybridization pattern of Fusarium non-solani species complex and positive control using DNA microarray.
A group of specific hybridization spots are visualized inside the square above and the spots remaining are representative of biotin (negative for
others species). The positive control is shown inside the below square and represents a sequence common to all fungal species.
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clustalo/). The sequencing was performed in the Molecu-
lar Epidemiology Laboratory at the Faculty of Medical Sci-
ences, State University of Campinas, São Paulo, Brazil and
the Medical Mycology Research Center, Chiba University,
Chiba, Japan.Antifungal susceptibility test
Antifungal susceptibility tests were performed for samples
LIF 2008, LIF 2009, LIF 2010, 1994 and EF111. Minimal in-
hibitory Concentrations (MIC) and minimal effective con-
centration (MEC) were determined following the micro
dilution method recommended by CLSI document M38-
A2, with minor changes. The conidia forms were suspended
by gently probing the colony with a sterile Pasteur pipette
tip to dislodge the conidia from the hyphal mat and the so-
lution; then, they were counted in a Neubauer chamber and
adjusted to a suspension containing 4 × 104 conidia/mL
(CLSI 2008; Teixeira et al. 2005). After that, conidia
were re-suspended in RPMI 1640 (Sigma) with L-
glutamine, without sodium bicarbonate, and buffered
with 0.165 mol/L 3-morpholinopropanesulfonic acid
(MOPS) in pH 7.0. The final suspension was distributed
in microdilution plates containing pre-defined incre-
mental concentrations of amphotericin B (AMB); itraco-
nazole (ITZ); voriconazole (VOR); micafungin (MCF);
5-flucytosine (5FC); miconazole (MCZ) and fluconazole
(FCZ). The plates were incubated at 35°C and fungal
growth was eye-observed after 24 h and 48 h. The MIC
was defined as the lowest drug concentration that caused
100% of inhibition of visible fungal growth for AMB, ITZ
and VCZ and as the lowest drug concentration that
caused 50% of inhibition of visible fungal growth for
MCZ, 5FC and FCZ and the MEC for MCZ was defined
as the lowest concentration of drug that leads to the
growth of small, rounded, compact hyphal forms as com-
pared to the hyphal growth seen in the growth control
well. The tests were performed in duplicate. American
Type Culture Collection strains Candida parapsilosis ATCC
22019, Candida krusei ATCC 6258, Candida albicans
ATCC 76615 and Candida albicans ATCC 90028 were used
for quality control.Table 1 Results of identification of Fusarium species accordin
microarray and DNA sequencing






LIF = Fungal Research Laboratory, FNSSC = Fusarium non-solani species complex, *SAntifungal agents
Micafungin, amphotericin B, 5-flucytosine, fluconazole,
voriconazole, itraconazole and miconazole in pre-
prepared dry plates (Eiken Chemical Co., Ltd., Tokyo)
(Makimura et al. 2005).
Results
Assessment of the Fusarium napiforme strains
All isolates from blood, skin biopsy and from air
were identified as Fusarium sp. by macroscopic and
microscopic characteristics, as Fusarium non-solani spe-
cies complex (FNSSC) DNA microarray methodology
(Figure 1) and as F. napiforme (non-solani) by sequen-
cing (Table 1). The sequences alignment showed two
F. napiforme distinct groups based on DNA homology:
one group with F. napiforme samples isolated from
blood (2009, 2010) and from skin biopsy (1994), and an-
other containing isolates for blood (2008) and air (F111),
as shown in Figure 2.
The susceptibility results can be seen in Table 2.
Discussion
Fusarium spp. are emerging as pathogens that can cause
life-threatening invasive opportunistic infections, mainly
among patients with bone marrow suppression and neu-
tropenia. Currently, Fusarium spp. are considered the
second most-common mold as cause of opportunistic
infection in these patients, being Aspergillus spp. the
first ones (Bodey et al. 2002; Cooke et al. 2009). Fusar-
ium spp. are also the most common cause of fungemia
with skin manifestations. (Bodey et al. 2002) reported
76% of 46 patients with hematologic malignancies or
solid tumors, considered to have definite Fusarium in-
fections, had skin lesions. (Nucci and Anaissie 2007) also
reported 61 hematopoietic stem cell transplant recipi-
ents with hematologic malignancies or solid tumors with
disseminated Fusarium infection, and metastatic skin le-
sions was the most frequent clinical presentation, occur-
ring in 46(75%) of patients.
The combination of cutaneous lesion and positive
blood cultures, involving or not other sites are the most
frequent pattern of disseminated fusariosis. The most
common clinical presentation is a persistently febrileg macro- and micro- morphological characteristics, DNA
DNA microarray DNA sequencing % Similarity*
FNSSC Fusarium napiforme 98
FNSSC Fusarium napiforme 99
FNSSC Fusarium napiforme 99
FNSSC Fusarium napiforme 99
FNSSC Fusarium napiforme 98
imilarity % for the comparison with NCBI database.
Figure 2 Clustal Omega multiple sequences alignment of Fusarium napiforme isolates by EF1α gene sequencing. The * symbol indicate a
100% homology for the specific base position. The square indicates one of the genetic variant groups.
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Table 2 Literature review of antifungal drugs evaluated for Fusarium species
Antifungal agent μg/ml (MEC/MIC)*
Author [reference] Fusarium species AMB FLU MCF ITZ VOR 5FC MCZ
(Melcher et al. 1993) Fusarium napiforme 1.16 10 1.25 >322.7
(Durand-Joly et al. 2003) Fusarium solani 1
(Rodriguez et al. 2003 ) Fusarium oxysporum 2 4
(Rothe et al. 2004) Fusarium oxysporum 2 >64 <2 >64
(Guzman-Cottrill et al. 2004) Fusarium solani 8 >64 8 >64
(Teixeira et al. 2005) Fusarium solani 2 128
(Ho et al. 2007) Fusarium solani 1 >16 4
(Neuburger et al. 2008) Fusarium proliferatum 4-8 >16 >16 8
(Tortorano et al. 2008) Fusarium verticillioides 1.53 3.33 1.74
Fusarium solani 1.25 >16 9.21
Fusarium proliferatum 1.7 >16 4.2
Fusarium oxysporum 2.3 >16 4
Fusarium subglutinans 3.3 10.8 5.6
(Xie et al. 2008) Fusarium solani 8
(Tezcan et al. 2009) Fusarium verticillioides 1-2 >8 4
(Bose et al. 2011) Fusarium spp. 2-4
(Liu et al. 2011) Fusarium solani 1 4
(Sekeroglu et al. 2012) Fusarium solani 0,5 >64 8
(Pereira et al. 2013) Fusarium solani >8 >8 0.5-0.128
Fusarium oxysporum ≤2 8
(Fanci et al. 2013) Fusarium verticillioides 2 8




isolate 2008 Fusarium napiforme 2-4 1-2 >16 >8 >8 >64 0.125-0.25
isolate 2009 Fusarium napiforme 2-4 1-2 >16 >8 2 >64 0.125-0.25
isolate 2010 Fusarium napiforme 2-4 1-2 >16 >8 4 >64 0.125-0.25
isolate 1994 Fusarium napiforme 2 1-2 >16 . > 8 4 >64 0.125
isolate F111 Fusarium napiforme 1 8 >16 >8 2 >64 0.5
*MEC =minimal effective concentration, MIC =minimum inhibitory concentration, MEC was defined for micafungin and MIC for the other drugs, AMB = amphotericin B,
FLU = fluconazole, MCF =micafungin, ITZ = itraconazole, VOR = voriconazole, 5FC = 5-flucytosine, MCZ =miconazole.
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develops disseminated characteristic skin lesions, with a
positive blood culture for a filamentous fungi (Nucci and
Anaissie 2007). This was the case of our patient.
The most common Fusarium involved in human in-
fections are F.solani, F.oxysporum and F.verticillioides
(Gupta et al. 2000; Tezcan et al. 2009). To our know-
ledge, we describe here the second case of disseminated
fusariosis caused by F.napiforme, and the first case with
identification confirmed by molecular techniques, in-
cluding sequencing.
The first invasive case by F.napiforme was described in
1993 (Melcher et al. 1993) in a patient diagnosed withacute myeloid leukemia, under cytoreduction and pro-
found granulocytopenia following high-dose of cytosine
arabinoside, mitoxantrone, and VP-16. Since then, no
other cases have been described.
The diagnosis of Fusarium in laboratory includes some
criteria such a positive direct mycological examination
showing typical septated hyphae branching at 45°. How-
ever, the identification of Fusarium to the species level is
often difficult and requires a specialized laboratory and
skilled personnel. In such situations, molecular biology
techniques might be helpful for the definitive diagnosis.
Furthermore, the early diagnosis of invasive disease
might be helpful to guide the correct antifungal therapy,
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2012; Busemann et al. 2009; Azor et al. 2009). In our
study, molecular methods allowed a faster and accurate
identification of the causative agent as belonging to
F.napiforme group. In addition, the strains F111 and
2008, from blood and air respectively, showed 100% se-
quencing alignment, suggesting that the the air may have
been the source of the infection. Samples 2009 and
2010, isolated from the blood, and skin isolate 1994 were
also aligned. Thus, it seems that we had two variants of
F.napiforme. Therapy for invasive fusariosis is a challen-
ging problem, mainly because Fusarium shows high
MICs to antifungal agents, and therefore, there is no
proven effective treatment regimen (Tezcan et al. 2009;
Guzman-Cottrill et al. 2004; Rothe et al. 2004). The
treatment of choice for invasive fusariosis is amphotericin
B. However, it is controversial, since there are reports
of Fusarium showing MICs for AMB ranging from 1 to
4 μg/mL. Triazoles, as voriconazole and posaconazole,
have also been used successfully (Pereira et al. 2013;
Tortorano et al. 2008). Furthermore, different Fusarium
can exhibit variable susceptibility patterns.
In the present case, patient was treated with ampho-
tericin B deoxicolate, initiated after laboratory confirm-
ation of Fusarium fungemia. However, the time between
the onset of symptoms and the blood culture was fifteen
days and the time between the blood culture and the
positive result for Fusarium was fifteen days more. The
isolate of F.napiforme in the present case was resistant
to amphotericin B, with MIC ranging from 2-4 μg/ml.
Delay in antifungal therapy plus the resistance profile
could have contributed to the patient’s death three days
after antifungal drug was initiated.
In conclusion, Fusarium spp. are emerging as a fungi
of relevance in medical mycology, since they are associ-
ated with low susceptibility profiles to antifungal drugs
and high mortality rate, mainly in imunocompromissed
patients. These facts highlight the importance for faster
and more accurate diagnostic tests, contributing to earl-
ier and precise diagnosis and treatment of this life-
threatening infection.
Nucleotide sequence accession numbers
The sequences determined in this study have been submit-
ted in (Sakai et al. 2014) and deposited in NCBI database
with the accession numbers KM099396 to KM099400.
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